Sienna Biopharmaceuticals, Inc.

Equities

SNNAQ

US82622H1086

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:46:25 10/05/2024 pm IST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2021	Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.	CI
2021	Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.	CI

Sienna Biopharmaceuticals, Inc. Announces the Resignation of Robert Nelsen as Member of the Board

October 04, 2018 at 01:36 am IST

Sienna Biopharmaceuticals, Inc. announced that on October 1, 2018, Robert Nelsen notified the Board of Directors of the company of his decision to resign as a member of the Board, effective immediately. Mr. Nelsen's resignation from the Board is due to other commitments.

Latest news about Sienna Biopharmaceuticals, Inc.

Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.	05/21/05	CI
Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.	05/21/05	CI
Sebacia, Inc. completed the acquisition of all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q).	09/20/09	CI
Motion For Case Conversion Approved for Sienna Biopharmaceuticals, Inc.	18/19/18	CI
Sienna Biopharmaceuticals, Inc.(OTCPK:SNNA.Q) dropped from NASDAQ Composite Index	16/19/16	CI
Motion for Case Conversion Filed by Sienna Biopharmaceuticals, Inc.	13/19/13	CI
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.	10/19/10	CI
Sebacia, Inc. entered into a sale purchase agreement to acquire all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $1.7 million.	10/19/10	CI
Notice of Selection of Successful Bidder Filed by Sienna Biopharmaceuticals, Inc.	05/19/05	CI
Bidding Procedure Approved for Sienna Biopharmaceuticals, Inc.	13/19/13	CI
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	13/19/13	CI
Motion for Asset Sale Filed by Sienna Biopharmaceuticals, Inc.	22/19/22	CI
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair	07/19/07	CI
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P Global BMI Index	19/19/19	CI
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P TMI Index	19/19/19	CI
Sienna Biopharmaceuticals, Inc. Filed for Bankruptcy	16/19/16	CI
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	09/19/09	CI
Sienna To Explore Strategic Alternatives	05/19/05	CI
Sienna Biopharmaceuticals, Inc.(OTCPK:SNNA.Q) dropped from Russell 2000 Dynamic Index	28/19/28	CI
Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%)	10/19/10	CI
Transcript : Sienna Biopharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-15-2019 03:55 PM	16/19/16
Sienna Biopharmaceuticals, Inc. Announces SNA-120 Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines	14/19/14	CI
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	09/19/09	CI
Certain Common Stock of Sienna Biopharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2019.	22/19/22	CI
Certain Stock Options of Sienna Biopharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2019.	22/19/22	CI

Chart Sienna Biopharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The Company's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SIENNA BIOPHARMACEUTICALS, INC.	-.--%	22
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.60%	11TCr
BIONTECH SE	-4.68%	2.43TCr
ARGENX SE	-0.82%	2.2TCr
GENMAB A/S	-10.12%	1.82TCr
WUXI APPTEC CO., LTD.	-42.12%	1.64TCr
BEIGENE, LTD.	-17.47%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.23TCr

Bio Therapeutic Drugs